Results 91 to 100 of about 2,626 (203)

Association of Tralokinumab and Adalimumab: Good Tolerance and Efficacy in a Case of Severe Atopic Dermatitis and Juvenile Idiopathic Arthritis

JEADV Clinical Practice
Atopic dermatitis is a chronic inflammatory and pruritic skin disease. The combination of tralokinumab with adalimumab in the treatment of inflammatory diseases had not yet been documented.
F. Rakotonandrasana, E. Puzenat, A. Ducournau, D. Popescu   +3 more
doaj   +1 more source

Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes

Journal of Clinical Medicine
Background/Objectives: Tralokinumab, a fully human monoclonal antibody targeting IL-13, has shown efficacy and safety in clinical trials and real-life studies for atopic dermatitis (AD). However, data on its effectiveness across AD phenotypes are limited.
Francesca Barei, Paolo Calzari, Elena Pezzolo, Maddalena Napolitano, Mariateresa Rossi, Mario Bruno Guanti, Francesca Caroppo, Anna Belloni Fortina, Cataldo Patruno, Anna Campanati, Tommaso Bianchelli, Giovanni Marco D’Agostino, Eustachio Nettis, Francesco Pugliese, Francesca di Vico, Ilaria Trave, Emanuele Cozzani, Luca Stingeni, Katharina Hansel, Matilde Dall’Olio, Laura Grigolato, Rosa Coppola, Vincenzo Panasiti, Martina Maurelli, Giampiero Girolomoni, Michela Ortoncelli, Simone Ribero, Angelo Valerio Marzano, Silvia Mariel Ferrucci   +28 more
openaire   +5 more sources

Improvement of Dupilumab‐Induced Psoriasiform Eruption Following a Switch to Tralokinumab

JEADV Clinical Practice
Biologic therapies have transformed the management of atopic dermatitis (AD) and prurigo nodularis (PN), yet paradoxical adverse events such as dupilumab‐induced psoriasiform eruption (DPE) are increasingly recognized.
Masato Mizuashi, Yoshinori Sasaki
doaj   +1 more source

Biologic agents for asthma treatment [PDF]

, 2019
Most treatment strategies for asthma currently include inhaled corticosteroids, with the addition of long-acting beta-2-agonists or leukotriene modifiers, if necessary. However, some patients may not respond to conventional treatment.
김성렬, 이재현
core   +1 more source

Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy

Dermatology and Therapy
Introduction A systematic literature review and network meta-analysis (NMA) were conducted to compare the short-term efficacy of lebrikizumab to other biologic and Janus kinase (JAK) inhibitor monotherapies approved for moderate-to-severe atopic ...
Jonathan I. Silverberg, Thomas Bieber, Amy S. Paller, Lisa Beck, Masahiro Kamata, Luis Puig, Marni Wiseman, Khaled Ezzedine, Alan D. Irvine, Peter Foley, James Del Rosso, Linda Stein Gold, Erin Johansson, Martin Dossenbach, Gaia Gallo, Buelent Akmaz, Marta Casillas, Andrei Karlsson, Tristan Curteis, Raj Chovatiya   +19 more
doaj   +1 more source

Tralokinumab-ldrm

American Journal of Health-System Pharmacy, 2022
openaire   +2 more sources

GUIDELINESItalian S3-guideline on the treatment of atopic eczema - Part 1: Systemic therapy, adapted from euroguiDerm by the Italian Society of Dermatology and StD (SIDemaSt), the Italian association of Hospital Dermatologists (aDoI) and the Italian Society of allergological and environmental Dermatology (SIDaPa) [PDF]

SIDeMaST (Società Italiana di Dermatologia Medica, Chirurgica, Estetica e delle Malattie Sessualmente Trasmesse) contributed to the development of the present guideline on the systemic treatment of chronic plaque psoriasis.
Amato S., Amerio P., Arents B. W., Argenziano G., Aszodi N., Avila Valle G. L., Barbarot S., Bieber T., Brough H. A., Calzavara-Pinton P., Chiricozzi A., Christen-Zach S., Corazza M., Cusano F., Deleuran M., Dittmann M., Dressler C., Fink-Wagner A. H., Flohr C., Fosse N., Gaspar K., Gerbens L. A., Gieler U., Girolomoni G., Gisondi P., Gregoriou S., Kinberger M., Mortz C. G., Naldi L., Nast A., Nygaard U., Patruno C., Pigatto P. D., Quaglino P., Redding M., Rehbinder E. M., Ring J., Rossi M., Serra-Baldrich E., Simon D., Stingeni L., Szalai Z. Z., Szepietowski J. C., Tonon F., Torrelo A., Werfel T., Wollenberg A.   +46 more
core   +4 more sources

Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis

Health Technology Assessment
Background Atopic dermatitis is a chronic relapsing inflammatory skin condition. One of the most common skin disorders in children, atopic dermatitis typically manifests before the age of 5 years, but it can develop at any age.
Steven J Edwards, Charlotta Karner, Tracey Jhita, Samantha Barton, Gemma Marceniuk, Zenas Z N Yiu, Miriam Wittmann   +6 more
doaj   +1 more source

Incidence of upper respiratory tract infections with biological therapies in moderate to severe atopic dermatitis: a systematic review and meta-analysis

Frontiers in Medicine
IntroductionAtopic dermatitis (AD) is a chronic inflammatory skin condition affecting 5%−20% of children and 2%−10% of adults worldwide. Treatment for moderate-to-severe AD includes biologics like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors
Rose Alraddadi, Rose Alraddadi, Mulham Kalantan, Mulham Kalantan, Yara Aljefri, Yara Aljefri, Hadeel Maaddawi, Abdulrahman Alsamadani, Abdulrahman Alsamadani, Athoub Kadasa, Athoub Kadasa, Abdulrahman Softah, Abdulrahman Softah, Baraa Tabbakh, Baraa Tabbakh, Rahaf Alturkistani, Abdulhadi Jfri, Abdulhadi Jfri, Abdulhadi Jfri   +18 more
doaj   +1 more source

Tralokinumab and Acitretin for the Treatment of Lamellar Ichthyosis

JAMA Dermatology
This case report describes a man in his 30s who presented with severe and generalized congenital ichthyosis and was treated with a combination of tralokinumab and acitretin.
De Greef, Axel, Baeck, Marie
openaire   +3 more sources